Palnox 0.25mg Injection

उत्पाद विवरण

1. Technical Specifications

2. Product Description

Palnox 0.25mg Injection contains Palonosetron, a highly selective 5-HT receptor antagonist used to prevent nausea and vomiting caused by chemotherapy (CINV) or postoperative conditions (PONV).

It blocks serotonin activity on vagal nerve terminals in the gastrointestinal tract and in the chemoreceptor trigger zone (CTZ) of the brain, preventing vomiting reflex.

Palonosetron has a longer half-life (40 hours) compared to older 5-HT antagonists (ondansetron, granisetron), making it effective for delayed nausea and vomiting.

3. Product Highlights

4. Therapeutic Uses

• Prevention of acute nausea & vomiting associated with initial and repeat courses of moderately or highly emetogenic chemotherapy.

• Prevention of delayed nausea & vomiting (due to long half-life).

• Postoperative nausea & vomiting (PONV) prevention.

5. Side Effects

Common:

• Headache

• Constipation

• Fatigue, dizziness

• Insomnia

Serious / Severe (rare):

• Hypersensitivity reactions (rash, itching, anaphylaxis)

• QT interval prolongation, arrhythmias

• Hypokalemia or electrolyte imbalance (with prolonged use)

6. Precautions

• Cardiac Patients: Use with caution in patients with history of arrhythmias, prolonged QT interval, or electrolyte abnormalities.

• Drug Interactions: Avoid combination with other QT-prolonging agents (amiodarone, sotalol, certain antibiotics/antifungals).

• Pregnancy & Lactation: Use only if clearly needed (limited human data).

• Hepatic/Renal Impairment: Generally safe; no major dose adjustment required.

• Children & Elderly: Dose adjustment based on body surface area (BSA) may be required in pediatric patients.